A Randomized, Parallel, Single Center, Comparison, Pilot Study Evaluating the Safety and Efficacy of Using Symlin Alongside Insulin in a Multiple Injection Port (I-PORT).
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2012
At a glance
- Drugs Pramlintide (Primary) ; Insulin
- Indications Diabetes mellitus; Type 1 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Nov 2011 Planned end date changed from 1 Dec 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 16 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.